Biogen Inc. (BIIB) Stock Analysis

Biogen Inc. (BIIB) Stock Analysis — AI Research | MarketCI

BIIB

Market Closed

Biogen Inc.

NASDAQHealthcare Drug Manufacturers - General

7.61K employees

CEO: Christopher A. Viehbacher

Founded: 1991

$196.58

+$0.00(+NaN%)

Market Cap

29.02B

Beta

0.18

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

BIIB Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for BIIB built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Buy

Pass %

71.43%

Score

5/7

Fair Value Estimate

Cash flow analysis • Multiple methods

$684.05

AI Price Target

Machine learning • Price prediction

$198.64

Market Sentiment

News & social media analysis

0.43

Value Investor Price

Classic value analysis

$78.66

Financial Health

Bankruptcy risk assessment

3.36

Quality Score

Financial strength rating

5.00

AI Investment Grade

Deep analysis of filings & news

58.00

Key Investment Highlights

Important factors affecting BIIB investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

65.85% Good

Conditions Met

27.00/41.00

Due Diligence Score

65.85%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Pass
	Fail
	Pass
	Fail
	Pass

Showing 1 to 6 of 46 conditions